(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/058465 A1

(51) International Patent Classification:
A61P 1/16 (2006.01) *A61K 9/20* (2006.01)
A61P 9/10 (2006.01) *A61K 38/48* (2006.01)
A61K 31/711 (2006.01)

(21) International Application Number:
PCT/EP2021/075548

(22) International Filing Date:
16 September 2021 (16.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/079,941 17 September 2020 (17.09.2020) US
63/114,232 16 November 2020 (16.11.2020) US

(71) Applicants: **ASTRAZENECA AB** [SE/SE]; 151-85 Södertälje (SE). **IONIS PHARMACEUTICALS, INC** [US/US]; 2855 Gazelle Ct., Carlsbad, California 92010 (US).

(72) Inventors: **TIVESTEN, Anna**; ASTRAZENECA AB, 151-85 Södertälje (SE). **DAVIES, Nigel**; ASTRAZENECA AB, 151-85 Södertälje (SE). **ELEBRING, Marie**; ASTRAZENECA AB, 151-85 Södertälje (SE). **GENNEMARK, Peter**; ASTRAZENECA AB, 151-85 Södertälje (SE). **MARUCCI, Mariagrazia**; ASTRAZENECA AB, 151-85 Södertälje (SE). **CLEMMENSEN, Niclas**; ASTRAZENECA AB, 151-85 Södertälje (SE). **MATIC, Hanna**; ASTRAZENECA AB, 151-85 Södertälje (SE). **PUTRA, Okky**; ASTRAZENECA AB, 151-85 Södertälje (SE). **UPADHYAY, Pratik Pankaj**; ASTRAZENECA AB, 151-85 Södertälje (SE). **WALTER, Katrin**; ASTRAZENECA AB, 151-85 Södertälje (SE). **RÅDEVIK, Andreas**; ASTRAZENECA AB, 151-85 Södertälje (SE). **TILLMAN, Lloyd**; Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, California 92010 (US). **DELLAMARY, Luis**; Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, California 92010 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION




FIG. 1

(57) Abstract: A pharmaceutical composition comprising A) one or more ASO or a pharmaceutically acceptable salt thereof; B) one or more permeation enhancer; C) one or more optional pharmaceutically acceptable excipient; and D) one or more optional coating. Said composition for use in the treatment, prevention, or amelioration of a disease associated with PCSK9 or PNPLA3 in a subject.

WO 2022/058465 A1

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*